Erinlar Capsule

Erinlar Capsule 150 mg Introduction

Erinlar Capsule 150 mg is a prescription medication used for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults. It is a kinase inhibitor that is taken orally. Erinlar Capsule 150 mg is available in the form of capsules, and is usually prescribed in a 150 mg dose. It is usually taken once a day, with or without food.

Uses for Erinlar Capsule 150 mg

Erinlar Capsule 150 mg is approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults. Specifically, it is used for patients with ALK-positive tumor who have been treated with or are intolerant to crizotinib. Erinlar Capsule 150 mg has also been approved for the treatment of metastatic NSCLC in patients with advanced ALK-rearranged NSCLC who have received prior chemotherapy.

Brand Name	Erinlar
Type	Capsule
Weight	150 mg
Generic	Ceritinib
Manufacturer	Genvio Pharma Ltd.
Available in	English বাংলা

Mechanism of Action

Erinlar Capsule 150 mg works by targeting and inhibiting anaplastic lymphoma kinase (ALK), which is an oncogene that can cause the tumors to grow abnormally. By inhibiting this enzyme, ceritinib has been show to have significant anti-cancer effects.

How Long Does It Take to Work?

The exact time it takes for ceritinib to start working may vary from patient to patient, but it generally takes a few weeks to show signs of efficacy. Most patients will start to experience fewer symptoms and/or lessened tumor growth over the course of a few months.

Absorption

Erinlar Capsule 150 mg is absorbed in the stomach and intestines after oral ingestion. It is then distributed to tissues and other organs in the body.

Route of Elimination

Erinlar Capsule 150 mg is eliminated via the kidneys and gastrointestinal tract. The drug metabolizes predominantly into active metabolites which are eventually eliminated from the body as urine.

Dosage

Patients should be selected for treatment of metastatic NSCLC with Ceritinib based on the presence of ALK positivity in tumor specimens. The recommended dose of Ceritinib is 450 mg orally once daily with food until disease progression or unacceptable toxicity. If a dose of Ceritinib is missed, that dose should be made up unless the next dose is due within 12 hours. If vomiting occurs during the course of treatment, an additional dose should not be administered and the next scheduled dose of Ceritinib should be continued. Or, as directed by the registered physician.

The usual recommended dosage of ceritinib for adults is a 150 mg tablet once a day taken with or without food. It is important to take the tablet at the same time each day to ensure levels remain constant in the body. The dose may be adjusted based on the individual's response and tolerability. If a dose is missed, it should be taken as soon as possible; however, if it is close to the time for the next dose, the missed dose should be skipped and the regular schedule should continue.

Administration

Erinlar Capsule 150 mg is taken orally, once a day. It should be taken at the same time each day with or without food to ensure levels remain constant in the body. If a dose is missed, it should be taken as soon as possible; however, if it is close to the time for the next dose, the missed dose should be skipped and the regular schedule should continue.

Side Effects

Common side effects associated with ceritinib include: diarrhea, nausea, vomiting, abdominal pain, anemia, loss of appetite, fatigue, edema, headache, decreased white blood cell count, increased liver enzymes, constipation, joint pain, and rash. Serious side effects include: pancreatitis, interstitial lung disease, liver toxicity, severe diarrhea, and QT prolongation. It is important to speak with your doctor about any side effects that may cause concern.

Toxicity

Erinlar Capsule 150 mg is generally a well-tolerated drug, however, potential toxicity may occurs with the drug, especially related to liver and renal function. Additionally, electrocardiographic (ECG) changes associated with QT prolongation may be observed with ceritinib therapy. Patients should be closely monitored for potential toxicities, and dosage may need to be adjusted if toxicity occurs.

Precautions

Because ceritinib can cause QT prolongation, patients should be monitored for changes in heart rate and ECG, and drugs that may cause QT prolongation should be avoided or used cautiously. Additionally, it is important to inform your doctor of any other medications, supplements, and herbal remedies that are being taken while taking ceritinib.

Interactions

Erinlar Capsule 150 mg may interact with other medications, such as cytochrome P450 (CYP) 3A4 inhibitors. It is important to tell your doctor about any other medications, vitamins, and/or herbal supplements that you are taking before starting ceritinib. Additionally, certain products may need to be avoided due to potential drug interactions.

Disease Interactions

Erinlar Capsule 150 mg should not be used by people with severe hepatic impairment. Additionally, due to its potential to prolong QT interval, it should be used with caution in patients with a history of cardiac problems such as long QT syndrome and congestive heart failure.

Drug Interactions

Erinlar Capsule 150 mg may interact with certain medications such as cytochrome P450 3A4 inhibitors, certain antifungal medications, certain calcium channel blockers, and certain antibiotics. It is important to inform your doctor of any other medications you are taking before starting ceritinib.

Food Interactions

Erinlar Capsule 150 mg should be taken with or without food, however, it is important to maintain a consistent time of day to take the medication. Additionally, excessive intake of grapefruit and grapefruit juice is not recommended, as it can potentially increase the levels of ceritinib in the body.

Pregnancy Use

Erinlar Capsule 150 mg is categorized as a category D drug, meaning that it may lead to fetal harm when used during pregnancy. Women of childbearing potential should use effective contraception while taking ceritinib and for at least 3 months after therapy is complete.

Lactation Use

It is not known if ceritinib is present in human milk or if it can harm a nursing infant, therefore, women taking ceritinib should not breastfeed while taking the medication.

Acute Overdose

In the event of an overdose of ceritinib, get emergency medical help immediately. Overdoses of ceritinib may cause serious side effects or death.

Contraindication

Erinlar Capsule 150 mg should not be used by patients with severe hepatic impairment or those with a known hypersensitivity to ceratinib or any of its components.

Use Direction

Erinlar Capsule 150 mg is taken orally, once a day. It should be taken at the same time each day with or without food to ensure levels remain constant in the body. It is important to take the tablet at the same time each day to ensure levels remain constant in the body. The dose may be adjusted based on the individual's response and tolerability. If a dose is missed, it should be taken as soon as possible; however, if it is close to the time for the next dose, the missed dose should be skipped and the regular schedule should continue.